Wilson Sonsini's office in downtown Boulder supports the region’s thriving life sciences businesses and other growth enterprises. It features a core team that includes several partners, associates, and staff professionals—most of whom have strong ties to companies, universities, and business organizations in the Colorado area. The firm expects the office to grow based on clients’ needs, the strength of the market in the region, and related recruiting efforts.
Wilson Sonsini already represents clients in Colorado that fall into a range of life sciences sectors, including: drug discovery; biotech, genomics, and proteomics; screening and diagnostics; medical devices and supplies; pharmaceuticals; health services; and agtech and foodtech. In fact, the firm has advised on a number of recent life sciences venture capital financings, M&A transactions, and IPOs in the region, including the IPO of Edgewise Therapeutics, a leader in the search for lifesaving medicines for rare muscular disorders, and the Series A financing for Foresight Diagnostics, which has developed promising technology for the early detection of cancers.
The firm also represents other technology companies based in Colorado and throughout the region, including innovative companies such as Solid Power, an industry-leading developer of all-solid-state battery cells for electric vehicles, and Inspirato LLC, an innovative luxury travel subscription brand. Please see the Related News and Insights section below for more information.
Wilson Sonsini Goodrich & Rosati is pleased to present our 2023 PTAB Year in Review. We begin with a review of 2023 petition filings and outcomes at the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office. We then provide a summary of notable developments at the PTAB, including recent precedential and director review decisions. Next, we explore several appellate decisions relevant to PTAB trials. After that, we examine potential trends regarding motions to exclude and secondary considerations. Finally, we provide an update on discretionary denials of institution for parallel litigation.